Growth Metrics

Anaptysbio (ANAB) Cash from Financing Activities (2016 - 2025)

Anaptysbio filings provide 10 years of Cash from Financing Activities readings, the most recent being -$43.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 256.47% year-over-year to -$43.1 million, compared with a TTM value of -$132.6 million through Dec 2025, down 204.38%, and an annual FY2025 reading of -$132.6 million, down 204.38% over the prior year.
  • Cash from Financing Activities hit -$43.1 million in Q4 2025 for Anaptysbio, down from -$10.4 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $251.3 million in Q4 2021, with the low at -$50.5 million in Q2 2025.
  • Median Cash from Financing Activities over the past 5 years was $204000.0 (2021), compared with a mean of $11.6 million.
  • The sharpest move saw Cash from Financing Activities surged 199373.02% in 2021, then plummeted 3223.15% in 2023.
  • Year by year, Cash from Financing Activities stood at $251.3 million in 2021, then plummeted by 99.22% to $1.9 million in 2022, then crashed by 364.7% to -$5.2 million in 2023, then surged by 634.35% to $27.6 million in 2024, then crashed by 256.47% to -$43.1 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$43.1 million, -$10.4 million, and -$50.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.